ClinicalTrials.gg
CompletedNCT05329857Updated Apr 15, 2022

The Study Intends to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safety Profile of Test Product Compared to Reference Product Will be Evaluated.

An interventional study of Metformin and Vildagliptin 1000/50 mg in To Determine Bioequivalence Under Fed Conditions, sponsored by AET Laboratories Private Limited. Completed. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-15.

Sponsored by AET Laboratories Private Limited · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 6 years 3 months after the study started (first participant enrolled Dec 2015, registered Mar 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

To evaluate and compare the relative bioavailability and therefore the bioequivalence of fixed dose combination of Metformin and Vildagliptin Tablets 1000/50 mg manufactured by Oman Pharmaceuticals Products Co. LLC, Sultanate of Oman, with EUCREAS® 50/1000 mg tablets manufactured by Novartis Pharma GmbH, Germany, in Normal, Healthy, Adult, Male Human Subjects under Fed Conditions.

02

Conditions studied

  • To Determine Bioequivalence Under Fed Conditions
03

In context

Lead sponsor

AET Laboratories Private Limited is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male subjects aged between 18 and 45 years (both inclusive).
  2. Subjects' weight within the normal range according to normal values for the (18.50 to 30.00 kg/m2) with minimum of 50 kg weight.
  3. Subjects with normal health as determined by personal medical history, clinical examination and laboratory examinations within clinically acceptable normal range.
  4. Subjects having clinically acceptable 12-lead (ECG).
  5. Subjects having clinically acceptable chest X-Ray (PA view).
  6. Subjects having negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine and morphine).
  7. Subjects having negative alcohol breath test.
  8. Subjects willing to adhere to the protocol requirements and to provide written .
  9. No history or presence of smoking.
  10. No history or presence of alcoholism and drug of abuse.

Exclusion criteria

Exclusion Criteria:

  1. to Vildagliptin or Metformin or related class of drugs.
  2. History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder.
  3. Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 1 month of the study starting.
  4. History or presence of asthma, urticaria or other significant allergic reactions.
  5. History or presence of significant gastric and/or duodenal ulceration.
  6. History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumor.
  7. History or presence of cancer or basal or squamous cell carcinoma.
  8. Difficulty with donating blood.
  9. Difficulty in swallowing solids like tablets or capsules.
  10. Use of any prescribed medication during the last one month or OTC medication during last two weeks prior to Dosing in Period 01.
  11. Major illness during 3 months before screening.
  12. Donation of blood in the past 3 months before screening.
  13. Participation in drug research study within past 3 months.
  14. Consumption of grapefruit juice within 72.00 hours prior to dosing in Period 01 and xanthine-containing products, tobacco containing products or alcohol within 48.00 hours prior to dosing in Period 01.
  15. Positive screening test for any one or more: , and .
  16. History or presence of significant easy bruising or bleeding.
  17. History or presence of significant recent trauma.
  18. Subjects who have been on an abnormal diet (for whatever reason) during the four weeks preceding the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Metformin and Vildagliptin 1000/50 mg Tablet

    1 tablet of Metformin and Vildagliptin 1000/50 mg as single-dose administration

    Drug: Metformin and Vildagliptin 1000/50 mg

  • Active comparator
    EUCREAS® 50/1000 mg Tablet

    1 tablet of EUCREAS® 50/1000 mg (each film-coated tablet contains Vildagliptin 50 mg and Metformin hydrochloride 1000 mg) as single-dose administration

    Drug: Metformin and Vildagliptin 1000/50 mg

Interventions

  • DrugMetformin and Vildagliptin 1000/50 mg

    50 mg Vildagliptin + 1000 mg Metformin as single-dose per study period

06

What researchers measure

Primary outcomes

  1. Cmax of Vildagliptin and Metformin for the test and reference products

    The maximum concentration in plasma among observed concentrations at pre-specified time points

    Time frame: up to 24 hours

  2. AUC0-t of Vildagliptin and Metformin for the test and the reference products

    The area under the plasma concentration versus time curve from time 0 to the last measured concentration

    Time frame: up to 24 hours

Secondary outcomes

  1. AUC0-∞ of Vildagliptin and Metformin for the test and the reference products

    The area under the plasma concentration versus time curve from time 0 to to infinite time

    Time frame: up to 24 hours

  2. Tmax of Vildagliptin and Metformin for the test and the reference products

    The time to maximum measured plasma concentration

    Time frame: up to 24 hours

  3. T1/2 of Vildagliptin and Metfomin for the test and the reference products

    Plasma elimination half-life

    Time frame: up to 24 hours

  4. Kel of Vildagliptin and Metformin for the test and the reference products

    Elimination rate constant

    Time frame: up to 24 hours

  5. Number of treatment-related adverse events (AE) for the test and the reference products as assessed by guidance predefined in the protocol

    An AE is defined as any untoward medical occurrence in a subject administered the test or the reference product and which does not necessarily have a causal relationship with the treatment.

    Time frame: through study completion, an average of 1 month

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2015 to primary completion in Jan 2016, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2022
First posted
Apr 15, 2022
StartActual
Dec 2015
Primary completionActual
Jan 2016
CompletionActual
Mar 2016
Last update
Apr 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05329857
Lead sponsor
AET Laboratories Private Limited
Responsible party
Sponsor
First posted
Apr 15, 2022
Start date
Dec 2015
Primary completion
Jan 2016
Completion
Mar 2016
Last update
Apr 15, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion